アブストラクト
| Title | 肝細胞癌に対する最新の薬物療法 |
|---|---|
| Subtitle | 今月のテーマ (総論) 肝細胞癌に対する最新の薬物療法時代における各種治療法の現況と展望 |
| Authors | 吉治仁志1) |
| Authors (kana) | |
| Organization | 1)奈良県立医科大学消化器代謝内科 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 119 |
| Number | 5 |
| Page | 389-402 |
| Year/Month | 2022 / 5 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨: 肝細胞癌に対する薬物療法は, パラダイムシフトともいえるような大きな変化を遂げている. 分子標的治療薬として2009年にソラフェニブが認可された後は一次治療の臨床試験は失敗が続き, ようやく2017年にレンバチニブのソラフェニブに対する非劣性が示された. その後, 2019年に免疫チェックポイント阻害薬であるアテゾリズマブと血管新生阻害薬であるベバシズマブ併用療法を用いてソラフェニブに対する生存期間の延長が報告され, 薬物療法の「ゲームチェンジャー」として承認されている. 現在ではレゴラフェニブ, ラムシルマブ, カボザンチニブとともにこれら6つの薬剤が保険適応となっている. 2021年秋には肝癌診療ガイドラインの改訂が行われた. 本稿ではこの新ガイドライン: 2021年版(第5版)を中心に, 肝細胞癌に対する最新の薬物療法について概説する. |
| Practice | 臨床医学：内科系 |
| Keywords | 肝細胞癌, 薬物療法, ガイドライン, 分子標的治療薬, 免疫チェックポイント阻害薬 |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Cheng AL, Kang YK, Chen Z, et al : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 ; 25-34 : 2009
- 2) Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 ; 378-390 : 2008
- 3) Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a ran-domised phase 3 non-inferiority trial. Lancet 391 ; 1163-1173 : 2018
- 4) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 ; 1894-1905 : 2020
- 5) 肝癌診療ガイドライン, 第5版, 一般社団法人日本肝臓学会編, 金原出版, 2021
残りの99件を表示する
- 6) European Association for the Study of the Liver. Electronic address : Corrigendum to "EASL Clini-cal Practice Guidelines : Management of hepato-cellular carcinoma" [J Hepatol 69(2018)182-236]. J Hepatel 70 ; 817 : 2019
- 7) Marrero JA, Kulik LM, Sirlin CB, et al : Diagnosis, Staging, and Management of Hepatocellular Car-cinoma : 2018 Practice Guidance by the American Association for thc Study of Liver Diseases. He-patology 68 ; 723-750 : 2018
- 8) Kokudo N, Takemura N, Hasegawa K, et al : Clini-cal practice guidelines for hepatocellular carci-noma : The Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update. Hepatol Res 49 ; 1109-1113 : 2019
- 9) Kudo M, Izumi N, Kokudo N, et al : Management of hepatocellular carcinoma in Japan : Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology(JSH)2010 up-dated version. Dig Dis 29 ; 339-364 : 2011
- 10) Kudo M, Matsui O, Izumi N, et al : Transarterial chemoembolization failure/refractoriness : JSH-LCSGJ criteria 2014 update. Oncology 87(suppl 1) ; 22-31 : 2014
- 11) Kudo M, Han KH, Ye SL, et al : A Changing Para-digm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma : Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 9 ; 245-260 : 2020
- 12) Yoshiji H, Kuriyama S, Noguchi R, et al : An-giopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in he-patocellular carcinoma development in mice. Gut 54 ; 1768-1775 : 2005
- 13) Yoshiji H, Kuriyama S, Yoshii J, et al : Halting the interaction between vascular endothclial growth factor and its receptors attenuates liver carcino-genesis in mice. Hepatology 39 ; 1517-1524 : 2004
- 14) Yoshiji H, Kuriyama S, Yoshii J, et al : Involve-ment of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J Hepatol 41 ; 97-103 : 2004
- 15) Yoshiji H, Kuriyama S, Yoshii J, et al : Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carci-noma cells. Hepatology 28 ; 1489-1496 : 1998
- 16) Yoshiji H, Kuriyama S, Ways DK, et al : Protein kinase C lies on the signaling pathway for vascu-lar endothelial growth factor-mediated tumor de-velopment and angiogenesis. Cancer Res 59 ; 4413-4418 : 1999
- 17) Yoshiji H, Kuriyama S, Yoshii J, et al : Synergistic effect of basic fibroblast growth factor and vascu-lar endothelial growth factor in murine hepatocel-lular carcinoma. Hepatology 35 ; 834-842 : 2002
- 18) Morse MA, Sun W, Kim R, et al : The Role of An-giogenesis in Hepatocellular Carcinoma. Clin Can-cer Res 25 ; 912-920 : 2019
- 19) Douhara A, Namisaki T, Moriya K, et al : Predis-posing factors for hepatocellular carcinoma recur-rence following initial remission after transcathe-ter arterial chemoembolization. Oncol Lett 14 ; 3028-3034 : 2017
- 20) Kawamura Y, Kobayashi M, Shindoh J, et al : Lenvatinib-Transarterial Chemoembolization Se-quential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Ad-vanced Hepatocellular Carcinoma. Liver Cancer 9 ; 756-770 : 2020
- 21) Kudo M : A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden : Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 8 ; 299-311 : 2019
- 22) Kudo M, Ueshima K, Chan S, et al : Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function : A Proof-Of-Concept Study. Can-cers 11 ; 1084 : 2019
- 23) Abou-Alfa GK, Meyer T, Cheng AL, et al : Cabo-zantinib in Patients with Advanced and Progress-ing Hepatocellular Carcinoma. N Engl J Med 379 ; 54-63 : 2018
- 24) Bruix J, Qin S, Merle P, et al : Regorafenib for pa-tients with hepatocellular carcinoma who pro-gressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 ; 56-66 : 2017
- 25) Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafenib in patients with advanced hepato-cellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet On-col 20 ; 282-296 : 2019
- 26) Bruix J, Raoul JL, Sherman M, et al : Efficacy and safety of sorafenib in patients with advanced he-patocellular carcinoma : subanalyses of a phase III trial. J Hepatol 57 ; 821-829 : 2012
- 27) Iwamoto H, Niizeki T, Nagamatsu H, et al : Sur-vival Benefit of Hepatic Arterial Infusion Chemo-therapy over Sorafenib in the Treatment of Lo-cally Progressed Hepatocellular Carcinoma. Can-cers 13 ; 646 : 2021
- 28) Ueshima K, Ogasawara S, Ikeda M, et al : Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carci-noma. Liver Cancer 9 ; 583-595 : 2020
- 29) Finn RS, Zhu AX : Targeting angiogenesis in he-patocellular carcinoma : focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 9 ; 503-509 : 2009
- 30) Kudo M : A New Era in Systemic Therapy for Hepatocellular Carcinoma : Atezolizumab plus Bevacizumab Combination Therapy. Liver Can-cer 9 ; 119-137 : 2020
- 31) Cainap C, Qin S, Huang WT, et al : Linifanib ver-sus Sorafenib in patients with advanced hepato-cellular carcinoma : results of a randomized phase III trial. J Clin Oncol 33 ; 172-179 : 2015
- 32) Cheng AL, Kang YK, Lin DY, et al : Sunitinib ver-sus sorafenib in advanced hepatocellular cancer : results of a randomized phase III trial. J Clin On-col 31 ; 4067-4075 : 2013
- 33) Johnson PJ, Qin S, Park JW, et al : Brivanib ver-sus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carci-noma : results from the randomized phase III BRISK-FL study. J Clin Oncol 31 ; 3517-3524 : 2013
- 34) Zhu AX, Rosmorduc O, Evans TR, et al : SEARCH : a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carci-noma. J Clin Oncol 33 ; 559-566 : 2015
- 35) Abou-Alfa GK, Shi Q, Knox JJ, et al : Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced He-patocellular Carcinoma : Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol 5 ; 1582-1588 : 2019
- 36) Yau T, Hsu C, Kim TY, et al : Corrigendum to "Nivolumab in advanced hepatocellular carci-noma : Sorafenib-experienced Asian cohort analy-sis" [J Hepatol 71(2019)543-552]. J Hepatol 71 ; 1278 : 2019
- 37) Alrabadi NN, Abushukair HM, Ababnch OE, et al : Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in ad-vanced melanoma patients with anti-PD-1 pro-gression : a systematic review and meta-analysis. Clin Transl Oncol 23 ; 1885-1904 : 2021
- 38) Doycheva I, Thuluvath PJ : Systemic Therapy for Advanced Hepatocellular Carcinoma : An Update of a Rapidly Evolving Field. J Clin Exp Hepatol 9 ; 588-596 : 2019
- 39) 肝癌診療マニュアル, 第4版, 一般社団法人日本肝臓学会編, 医学書院, 2020
- 40) Ai L, Xu Z, Yang B, et al : Sorafenib-associated hand-foot skin reaction : practical advice on diag-nosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol 12 ; 1121-1127 : 2019
- 41) Howell J, Pinato DJ, Ramaswami R, et al : On-target sorafenib toxicity predicts improved sur-vival in hepatocellular carcinoma : a multi-centre, prospective study. Aliment Pharmacol Ther 45 ; 1146-1155 : 2017
- 42) Koschny R, Gotthardt D, Koehler C, et al : Diar-rhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 84 ; 6-13 : 2013
- 43) Matsuki R, Kawai K, Suzuki Y, et al : Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocel-lular Carcinoma. Liver Cancer 9 ; 358-360 : 2020
- 44) Kuzuya T, Ishigami M, Ito T, et al : Favorable ra-diological antitumor response at 2 weeks after starting lenvatinib for patients with advanced he-patocellular carcinoma. Hepatol Res 50 ; 374-381 : 2020
- 45) Takahashi A, Moriguchi M, Seko Y, et al : Impact of Relative Dose Intensity of Early-phase Len-vatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res 39 ; 5149-5156 : 2019
- 46) Kudo M, Moriguchi M, Numata K, et al : S-1 ver-sus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma(S-CUBE) : a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol 2 ; 407-417 : 2017
- 47) Llovet JM, Decaens T, Raoul JL, et al : Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed : results from the randomized phase III BRISK-PS study. J Clin Oncol 31 ; 3509-3516 : 2013
- 48) Rimassa L, Assenat E, Peck-Radosavljevic M, et al : Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma(METIV-HCC) : a final analysis of a phase 3, ran-domised, placebo-controlled study. Lancet Oncol 19 ; 682-693 : 2018
- 49) Zhu AX, Kudo M, Assenat E, et al : Effect of ever-olimus on survival in advanced hepatocellular carcinoma after failure of sorafenib : the EVOLVE-1 randomized clinical trial. JAMA 312 ; 57-67 : 2014
- 50) Yoshiji H, Kuriyama S, Hicklin DJ, et al : The vas-cular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites for-mation in the mouse hepatocellular carcinoma model. Hepatology 33 ; 841-847 : 2001
- 51) Yoshiji H, Kuriyama S, Hicklin DJ, et al : KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30 ; 1179-1186 : 1999
- 52) Zhu AX, Park JO, Ryoo BY, et al : Ramucirumab versus placebo as second-line treatment in pa-tients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH) : a randomised, double-blind, multicen-tre, phase 3 trial. Lancet Oncol 16 ; 859-870 : 2015
- 53) Kudo M, Galle PR, Llovet JM, et al : Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int 40 ; 2008-2020 : 2020
- 54) Kudo M, Hatano E, Ohkawa S, et al : Ramuciru-mab as second-line treatment in patients with ad-vanced hepatocellular carcinoma : Japanese sub-group analysis of the REACH trial. J Gastroen-terol 52 ; 494-503 : 2017
- 55) Yen CJ, Kudo M, Lim HY, et al : Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carci-noma and Elevated Alpha-Fetoprotein : Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer 9 ; 440-454 : 2020
- 56) Kudo M, Galle PR, Brandi G, et al : Effect of ramu-cirumab on ALBI grade in patients with ad-vanced HCC : Results from REACH and REACH-2. JHEP Rep 3 ; 100215 : 2021
- 57) De Luca E, Marino D, Di Maio M : Ramucirumab, A Second-Line Option For Patients With Hepato-cellular Carcinoma : A Review Of The Evidence. Cancer Manag Res 12 ; 3721-3729 : 2020
- 58) Yakes FM, Chen J, Tan J, et al : Cabozantinib(XL184), a novel MET and VEGFR2 inhibitor, si-multaneously suppresses metastasis, angiogene-sis, and tumor growth. Mol Cancer Ther 10 ; 2298-2308 : 2011
- 59) Kudo M, Tsuchiya K, Kato N, et al : Cabozantinib in Japanese patients with advanced hepatocellu-lar carcinoma : a phase 2 multicenter study. J Gas-troenterol 56 ; 181-190 : 2021
- 60) Trojan J : Cabozantinib for the Treatment of Ad-vanced Hepatocellular Carcinoma : Current Data and Future Perspectives. Drugs 80 ; 1203-1210 : 2020
- 61) Yoshiji H, Nagoshi S, Akahane T, et al : Evidence-based clinical practice guidelines for Liver Cirrho-sis 2020. J Gastroenterol 56 ; 593-619 : 2021
- 62) Yoshiji H, Nagoshi S, Akahane T, et al : Evidence-based clinical practice guidelines for liver cirrho-sis 2020. Hepatol Res 51 ; 725-749 : 2021
- 63) Tada T, Kumada T, Hiraoka A, et al : Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep 11 ; 14474 : 2021
- 64) Ueshima K, Nishida N, Hagiwara S, et al : Impact of Baseline ALBI Grade on the Outcomes of He-patocellular Carcinoma Patients Treated with Lenvatinib : A Multicenter Study. Cancers 11 ; 952 : 2019
- 65) Demirtas CO, D'Alessio A, Rimassa L, et al : ALBI grade : Evidence for an improved model for liver functional estimation in patients with hepatocellu-lar carcinoma. JHEP Rep 3 ; 100347 : 2021
- 66) Pinato DJ, Sharma R, Allara E, et al : The ALBI grade provides objective hepatic reserve estima-tion across each BCLC stage of hepatocellular carcinoma. J Hepatol 66 ; 338-346 : 2017
- 67) Vogel A, Merle P, Verslype C, et al : ALBI score and outcomes in patients with hepatocellular car-cinoma : post hoc analysis of the randomized con-trolled trial KEYNOTE-240. Ther Adv Med On-col 13 ; 17588359211039928 : 2021
- 68) Yukimoto A, Hirooka M, Hiraoka A, et al : Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in pa-tients with hepatocellular carcinoma. Jpn J Clin Oncol 49 ; 42-47 : 2019
- 69) Therasse P, Arbuck SG, Eisenhauer EA, et al : New guidelines to evaluate the response to treat-ment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 ; 205-216 : 2000
- 70) Choi H : Response evaluation of gastrointestinal stromal tumors. Oncologist 13(suppl 2) ; 4-7 : 2008
- 71) Eisenhauer EA, Therasse P, Bogaerts J, et al : New response evaluation criteria in solid tu-mours : revised RECIST guideline(version 1.1). Eur J Cancer 45 ; 228-247 : 2009
- 72) Nathan PD, Vinayan A, Stott D, et al : CT re-sponse assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer pa-tients treated with targeted therapies. Cancer Biol Ther 9 ; 15-19 : 2010
- 73) Stacchiotti S, Collini P, Messina A, et al : High-grade soft-tissue sarcomas : tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251 ; 447-456 : 2009
- 74) Edeline J, Boucher E, Rolland Y, et al : Compari-son of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for he-patocellular carcinoma. Cancer 118 ; 147-156 : 2012
- 75) Bruix J, Sherman M, Llovet JM, et al : Clinical management of hepatocellular carcinoma. Conclu-sions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 ; 421-430 : 2001
- 76) Choi H, Charnsangavej C, Faria SC, et al : Correla-tion of computed tomography and positron emis-sion tomography in patients with metastatic gas-trointestinal stromal tumor treated at a single in-stitution with imatinib mesylate : proposal of new computed tomography response criteria. J Clin Oncol 25 ; 1753-1759 : 2007
- 77) Kudo M, Kubo S, Takayasu K, et al : Response Evaluation Criteria in Cancer of the Liver(RECICL)proposed by the Liver Cancer Study Group of Japan(2009 Revised version). Hepatol Res 40 ; 686-692 : 2010
- 78) Seymour L, Bogaerts J, Perrone A, et al : iRECIST : guidelines for response critcria for use in trials testing immunotherapeutics. Lancet On-col 18 ; e143-e152 : 2017
- 79) El-Khoueiry AB, Sangro B, Yau T, et al : Nivolumab in patients with advanced hepatocel-luiar carcinoma(CheckMate 040) : an open-label, non-comparative, phasc 1/2 dose escalation and expansion trial. Lancet 389 ; 2492-2502 : 2017
- 80) Finn RS, Ryoo BY, Merle P, et al : Pembrolizumab As Second-Line Therapy in Patients With Ad-vanced Hepatocellular Carcinoma in KEYNOTE-240 : A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 38 ; 193-202 : 2020
- 81) Yau T, Hsu C, Kim TY, et al : Nivolumab in ad-vanced hepatocellular carcinoma : Sorafenib-experienced Asian cohort analysis. J Hepatol 71 ; 543-552 : 2019
- 82) Zhu AX, Finn RS, Edeline J, et al : Pembrolizu-mab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a non-randomised, open-label phase 2 trial. Lancet Oncol 19 ; 940-952 : 2018
- 83) Kudo M : Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Im-mune Checkpoint Inhibitor Therapy in Hepato-cellular Carcinoma. Liver Cancer 9 ; 479-490 : 2020
- 84) Sia D, Jiao Y, Martinez-Quetglas I, et al : Identifi-cation of an Immune-specific Class of Hepatocellu-lar Carcinoma, Based on Molecular Features. Gas-troenterology 153 ; 812-826 : 2017
- 85) Xue G, Romano E, Massi D, et al : Wnt/β-catenin signaling in melanoma : Preclinical rationale and novel therapeutic insights. Cancer Treat Rev 49 ; 1-12 : 2016
- 86) Harding JJ, Nandakumar S, Armenia J, et al : Pro-spective Genotyping of Hepatocellular Carci-noma : Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res 25 ; 2116-2126 : 2019
- 87) Kurebayashi Y, Ojima H, Tsujikawa H, et al : Landscape of immune microenvironment in hepa-tocellular carcinoma and its additional impact on histological and molecular classification. Hepatol-ogy 68 ; 1025-1041 : 2018
- 88) Ueno A, Masugi Y, Yamazaki K, et al : OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 61 ; 1080-1087 : 2014
- 89) Tateishi R, Koike K : Changing etiology of hepato-cellular carcinoma. J Gastroenterol 55 ; 125-126 : 2020
- 90) Tateishi R, Uchino K, Fujiwara N, et al : A nation-wide survey on non-B, non-C hepatocellular carci-noma in Japan : 2011-2015 update. J Gastroenterol 54 ; 367-376 : 2019
- 91) Younossi ZM, Henry L : Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 3 ; 100305 : 2021
- 92) Tokushige K, Ikejima K, Ono M, et al : Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 56 ; 951-963 : 2021
- 93) Tokushige K, Ikejima K, Ono M, et al : Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res 51 ; 1013-1025 : 2021
- 94) Dudek M, Pfister D, Donakonda S, et al : Auto-aggressive CXCR6+ CD8 T cells cause liver im-mune pathology in NASH. Nature 592 ; 444-449 : 2021
- 95) Pfister D, Nunez NG, Pinyol R, et al : NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592 ; 450-456 : 2021
- 96) Aron-Wisnewsky J, Vigliotti C, Witjes J, et al : Gut microbiota and human NAFLD : disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17 ; 279-297 : 2020
- 97) Behary J, Amorim N, Jiang XT, et al : Gut micro-biota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepato-cellular carcinoma. Nat Commun 12 ; 187 : 2021
- 98) Huppert LA, Gordan JD, Kelley RK : Checkpoint Inhibitors for the Treatment of Advanced Hepa-tocellular Carcinoma. Clin Liver Dis 15 ; 53-58 : 2020
- 99) Aoki T, Kudo M, Ueshima K, et al : Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Block-ade. Cancers 12 ; 3048 : 2020
- 100) Kato Y, Tabata K, Kimura T, et al : Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One 14 ; e0212513 : 2019
- 101) Mo DC, Luo PH, Huang SX, et al : Safety and effi-cacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers : A systematic review. Int Immunophar-macol 91 ; 107281 : 2021
- 102) Yoshiji H, Noguchi R, Namisaki T, et al : Combina-tion of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion develop-ment in a non-diabetic rat model of steatohepati-tis. J Gastroenterol 49 ; 1421-1429 : 2014
- 103) Ogawa H, Kaji K, Nishimura N, et al : Lenvatinib prevents liver fibrosis by inhibiting hepatic stel-late cell activation and sinusoidal capillarization in experimental liver fibrosis. J Cell Mol Med 25 ; 4001-4013 : 2021
- 104) Yoshiji H, Kuriyama S, Yoshii J, et al : Vascular endothelial growth factor and receptor interac-tion is a prerequisite for murine hepatic fibro-genesis. Gut 52 ; 1347-1354 : 2003
